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Abstract
ABL1 tyrosine-kinase inhibitors (TKI) are a front-line therapy for chronic myelogenous leukemia 
and represent the best known examples of targeted cancer therapeutics. However, the dynamic 
uptake of low molecular weight TKIs into cells and their intracellular behavior is largely unknown 
due to the difficulty of observing non-fluorescent small molecules at subcellular resolution. Here 
we report the direct label-free visualization and quantification of two TKI drugs – imatinib and 
nilotinib inside living cells using hyperspectral stimulated Raman scattering imaging. Both drugs 
were enriched over 1000-fold in lysosomes as a result of their lysosomotropic properties. In 
addition, low solubility appeared to contribute significantly to the surprisingly large accumulation 
of nilotinib. We further show that the lysosomal trapping of imatinib was reduced by more than 
10-fold when using chloroquine simultaneously, suggesting that chloroquine may increase the 
efficacy of TKIs through lysosome mediated drug-drug interaction besides the commonly 
proposed autophagy inhibition mechanism.
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tINTRODUCTION
The Abelson tyrosine kinase (ABL1) is an enzyme which is ubiquitously expressed in cells. 
Its tyrosine phosphorylation capacity is tightly regulated. Genetic damage in a hematopoietic 
cell can lead to a t(9;22)(q34,q11) chromosome translocation resulting in expression of the 
chimeric BCR-ABL1 oncoprotein, in which ABL1 is constitutively active. This oncoprotein 
causes chronic myeloid leukemia (CML), which is invariably fatal if left untreated1. 
Imatinib (Gleevec®, Novartis Pharmaceuticals) is the first-in-class ABL1 tyrosine kinase 
inhibitor, used for the treatment of Philadelphia chromosome positive CML; nilotinib 
(Tasigna®, Novartis Pharmaceuticals) is a more potent and more selective drug, used in the 
same indication2. Whereas imatinib and nilotinib are ATP-competitive inhibitors of ABL 
which bind within the substrate ATP binding pocket of the kinase, two other agents, GNF-2 
and GNF-5 are compounds which specifically inhibit the kinase activity of ABL1 via an 
allosteric mechanism3.
Recently chloroquine, a drug used to treat malaria, has been found to have synergistic effect 
with imatinib in models of CML and gastrointestinal stromal tumors (GIST)4,5. Chloroquine 
significantly increased imatinib-induced BCR-ABL expressing cell death from ~50% to 
75%. Similar effects were observed in GIST cells. It was suggested that chloroquine, known 
to inhibit the autophagy pathway by neutralizing lysosomal pH6, could prevent the imatinib-
treated CML and GIST cells from going through the autophagy-related survival mechanism, 
and thus providing the synergistic effect. This exciting possibility initiated clinical trials 
with combination drug treatment regimens in hematopoietic malignancies as well as in solid 
tumors. While autophagy inhibition was frequently proposed as a mechanism of synergistic 
effect of chloroquine or its hydroxychloroquine analog with targeted or cytotoxic cancer 
therapeutic agents4,5,7–9, studies on both small cell lung cancer and breast cancer cells found 
that the effects of chloroquine were non-specific and independent of autophagy10,11. The 
contribution of autophagy inhibition remains unclear in the synergistic effects observed in 
combination drug treatment.
The molecular biology, pharmacology and tissue distribution of imatinib and nilotinib are 
well established. However, little is known about their intracellular distribution. Eukaryotic 
cells provide compartmental conditions for most biochemical reactions. Endogenous small 
molecules, including inorganic ions, cofactors, amino acids, lipids and carbohydrates, are 
regulated and usually dependent on specific transporter to cross plasma, organelle and 
nuclear membranes12. In contrast, pharmaceuticals and xenobiotics, most of which have 
both lipophilic and hydrophilic groups, can only passively diffuse through the lipid-bilayer 
membrane in neutral form. Despite the subcellular behavior of drugs and xenobiotics being 
of great importance in pharmacology, toxicology and drug discovery, the membrane 
permeability, cytosol and organelle distribution, and transportation of such agents are poorly 
understood. The main reason for this is the lack of a technology capable of observing low-
molecular-weight (LMW) compounds without labeling, and with enough spatial and 
temporal resolution to obtain time-lapse subcellular information.
Confocal Raman microscopy, a non-invasive and label-free imaging technique, has been 
shown to be able to trace drugs in living cells, but with limited speed and sensitivity13–17. 
Fu et al. Page 2
Nat Chem. Author manuscript; available in PMC 2015 January 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tStimulated Raman Scattering (SRS) microscopy, with much improved sensitivity achieved 
by using a high-frequency phase-sensitive lock-in detection scheme, allows high-speed 
label-free chemical imaging with 3-D subcellular spatial resolution18. It has been used for 
the imaging of lipids, proteins, DNA and other high concentration species in cells and 
tissue19–21. However, direct imaging of the intracellular distribution of small drug-like 
molecules has not been demonstrated. Traditional SRS microscopy probes one Raman band 
at a time. Biological cells have strong background SRS signals, especially in the fingerprint 
region. In order to distinguish different molecules, both multiplex SRS and hyperspectral 
SRS (hsSRS) microscopy which allow imaging at multiple Raman frequencies have been 
developed22–25, enabling direct imaging of LMW compounds inside a living cell.
Here we report the first direct observation and quantification of imatinib, nilotinib and 
GNF-2/-5, so-called 1st, 2nd and 3rd generations of TKIs in living CML cells using hsSRS 
imaging. We show that both the lysosomotropic property and the solubility of these drugs 
play important roles in their uptake and selective accumulation inside cellular organelles. 
We also directly studied the interplay between chloroquine and these TKIs in living cells, 
providing new insights into the mechanism of their synergistic effect at the subcellular level.
RESULTS AND DISCUSSION
Spontaneous Raman spectroscopy of drug molecules
To identify suitable spectral range for hsSRS imaging, we first measured the spontaneous 
Raman spectra of five drug molecules with a commercial Horiba-Jobin-Yvon Raman 
spectrometer. The chemical structures of the drug molecules are shown in Fig. 1a and their 
corresponding Raman spectra are shown in Fig. 1b. The spectral regions of particular 
interests are around 1300 cm−1 and 1600 cm−1. Both imatinib and nilotinib exhibited strong 
Raman signals in these two regions, while GNF-2 and GNF-5 exhibited strong Raman signal 
in the 1600 cm−1 region. The Raman peaks around 1300 cm−1 were tentatively assigned to 
the C-C stretching of the bond between pyrimidine and pyridine based on Raman 
measurements of a tool compound 4-(3-pyridinyl)-2-pyrimidine amine; while the Raman 
peaks around 1600 cm−1 were attributed to overlapping aromatic ring stretching26. 
Chloroquine had a major peak around 1370 cm−1, which was attributed to quinoline ring 
stretching mode27.
hsSRS imaging of drug accumulation inside cells
We imaged imatinib and nilotinib treated cells with a total of 20 SRS frames evenly spaced 
between 1236 cm−1 and 1497 cm−1 at a speed of 1.6 sec/frame. Fig. 2a and 2b show SRS 
images at 1305 cm−1 of 20 μM imatinib and nilotinib treated BaF3/BCR-ABL1 cells, 
respectively (supplementary Movie S1 show the hsSRS imaging data). Compared with the 
control cell treated only with DMSO (Fig. 2c), we observed several bright spots within both 
drug treated cells which resulted from drug accumulation inside the cell. The SRS spectra of 
the enclosed regions of interest (ROI, yellow circle) matched that of the SRS spectra of 
drugs in solution (Fig. 2d and 2e), but were different from cytosol spectra which had a broad 
peak around 1340 cm−1 (assigned to C-H deformation). Moreover, the drug spectra were 
similar to their spontaneous Raman counterpart (Fig. 1b) except for reduced spectral 
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tresolution due to the limitation of the current spectral focusing hsSRS setup. In both cases, 
SRS spectra substantiated that the bright spots within cells are indeed accumulation of 
drugs, not metabolic or morphological responses of cells. Because SRS signal of drugs 
exhibit linear relationship with concentration (supplementary Fig. S2), the concentration of 
drugs inside cells can be quantitatively determined based on calibrations of drug solutions at 
known concentration. In the cytosol, we did not observe cytosol SRS spectral shape change 
when compared to control cells without drug treatment (Fig. 2f), suggesting that cytosolic 
drug concentrations were below the current limit of detection (1–2 mM).
To examine whether the accumulation of drugs was due to the binding of drugs to their 
targets, we imaged the drug uptake in BaF3/wt cells, which lack the BCR-ABL1 protein. 
Similar drug accumulations were observed in these control cells compared to that of BaF3/
BCR-ABL1 cells (supplementary Fig. S3). Further comparison of the spectral intensities of 
accumulated drugs revealed that drug accumulations were comparable in these two types of 
cells (supplementary Fig. S3), suggesting that drug accumulations are independent of their 
binding to their target protein BCR-ABL1.
Determining the mechanism of drug accumulation
The three-dimensional distributions of drug accumulation revealed that both imatinib and 
nilotinib accumulated outside cell nuclei (supplementary Movie S2). Because both drugs are 
weak bases that can be protonated in acidic environment, the most likely sites of 
accumulation are lysosomes or related acidic organelles. To examine this hypothesis, we 
imaged drug treated BaF3/BCR-ABL1 cells that were simultaneously labeled with 
Lysotracker Red (Invitrogen), a fluorescent marker for lysosomes. Cells were incubated in 
the presence of 20 μM imatinib or nilotinib together with 50 nM Lysotracker Red for 4 
hours before imaging. Both the SRS image and the two-photon fluorescence image were 
acquired simultaneously. Fig. 3a and 3d show the maximum intensity projection of three-
dimensional SRS images of cells treated with imatinib or nilotinib at 1305 cm−1, while Fig. 
3b and 3e show the maximum intensity projection of three-dimensional fluorescence images 
of the same cells (supplementary Movies S2 shows the corresponding three-dimensional 
sectioning images with 0.5 μm Z step). In both cases, the exact spatial overlap confirms that 
drugs are accumulated in lysosome or lysosome-related acidic organelles (Fig. 3c and 3f). 
Lysosomes were also stained in control cells not treated with any drug, but they did not 
show any difference in SRS intensity compared to the rest of the cytoplasm (Fig. 3g–i).
It is known that many weak bases can readily diffuse through cell membranes in their 
neutral form, but will be trapped within lysosomes in the protonated form due to the pH 
difference between the two regions separated by the lysosomal membrane. This is 
commonly referred to as the lysosomotropic effect, which was discussed in great detail by 
C. De Duve in 197428. The much lower pH (pH = 4.5–5) of the lysosome compared with 
that of the cytoplasm (pH = 7–7.5) provides a driving force for intra-lysosomal 
accumulation of weak bases. Based on De Duve’s theory, drug molecules in their neutral 
form permeate the membrane at a much higher rate compared to their protonated form. The 
maximum concentration ratio is determined by the ratio of the lysosomal pH and 
extracellular pH. Assuming the pH in the lysosomes to be 4.5 and that in the medium to be 
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t7.2, that ratio is 500. For weakly basic drugs that have pKa lower than 7 or drugs that have a 
high ratio of permeability rates, the maximum concentration ratio is lower.
One of the best known lysosomotropic agents is the anti-malaria drug chloroquine. To 
quantitatively examine the uptake of chloroquine into lysosomes, we incubated BaF3/BCR-
ABL1 cells with 50 μM chloroquine for 2 hours. hsSRS imaging showed that the 
chloroquine accumulated inside lysosomes to give an average concentration of 50 mM 
(supplementary Fig. S4). Based on the SRS signal intensities, we calculated the 
concentration ratios of lysosomal drug to extracellular drug: chloroquine was enriched by 
1000 (±128) fold, imatinib by 933 (±354) fold, and nilotinib by 2520 (±1520) fold. Both 
chloroquine and imatinib have pKa values larger than 8 (chloroquine pKa1 = 10.2, pKa2 = 
8.3, imatinib pKa = 8.1), leading to an accumulation of ~1000-fold, a factor of 2 larger than 
predicted. The difference could be due to our rather simplified prediction model. A more 
complicated model taking into account the diffusion property, adsorption to lipids, and 
electrical attraction or repulsion has been shown to predict higher accumulation of 
chloroquine and other drugs29. Surprisingly, nilotinib accumulated by a factor of 80 times 
more than its predicted value of 32 based on its measured pKa of 6. We believe this is due to 
the relatively poor solubility of nilotinib at acidic pH (measured solubility is 2.6 μM at pH 2 
and 0.4 μM at pH 6.8). As the accumulation of nilotinib in the lysosome exceeds its 
solubility, precipitation of nilotinib follows. The precipitation shifts the equilibrium such 
that more nilotinib molecules are transported into the lysosome and results in a much higher 
apparent nilotinib concentration inside the lysosome. In contrast, both imatinib and 
chloroquine have excellent water solubility at pH 4–5 (>400 mM) and therefore would not 
be subject to precipitation.
We further lowered the extracellular concentration of both drugs to determine whether the 
precipitation of nilotinib was responsible for the observed abnormal accumulation. When the 
extracellular concentration of both drugs were lowered from 20 μM to 4 μM, lysosomal drug 
concentration decreased by roughly 4- to 5-fold for imatinib, but by at least 30-fold for 
nilotinib (supplementary Fig. S5). The concentration-independent enrichment of imatinib 
(within experimental error) is consistent with the acid-base equilibrium predictions. In 
contrast, the strong concentration dependence of nilotinib enrichment supports our 
hypothesis that its precipitation plays an important role in lysosomal trapping: when the 
enriched nilotinib concentration is below its solubility, precipitation will not occur and the 
enrichment ratio will follow that predicted by acid-base equilibrium. Determination of the 
exact enrichment ratio for nilotinib without precipitation is limited by the inaccuracy in 
determining lysosomal drug SRS spectra at sub-mM concentration. Nonetheless, we show to 
our knowledge for the first time that the precipitation of low solubility compounds, in 
addition to the protonation of weak basic groups, provides another trapping mechanism for 
their lysosomal enrichment. The lysosomotropic model should therefore be modified to 
include the solubility equilibrium to better describe situations where the compound under 
study has low solubility (Fig. 3j).
To further examine whether autophagy plays an important role in imatinib/nilotinib uptake 
into lysosomes, we pre-incubated the BaF3/BCR-ABL1 cells with 5 mM 3-methyladenine 
(3MA) for 4 hours, before incubating the cells with drugs (20 μM) for another 2 hours. 3MA 
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inhibition of type III phosphatidylinositol 3-kinases30. No significant difference in 
lysosomal drug accumulation was observed for either imatinib or nilotinib (supplementary 
Fig. S5), suggesting that autophagy is not responsible for the observed drug enrichment in 
lysosomes.
For drugs that have pKa < 4.5, we do not expect to observe drug accumulation in lysosomes. 
GNF-2 and GNF-5 are two highly selective allosteric inhibitors of BCR-ABL13. Both drugs 
are predominantly unprotonated at pH 4–7. We incubated BaF3/BCR-ABL1 cells with the 
two drugs at a concentration of 50 μM for 2 hours. As predicted, hsSRS imaging did not 
reveal any significant accumulation in lysosomes (Fig. 4a). SRS images at 1600 cm−1 
showed that neither drug penetrated into the nucleus. Therefore, the nucleus spectra did not 
change while the cytoplasm spectra had moderate increases in intensity around 1600 cm−1 
(Fig. 4b). After subtracting the nucleus spectra from the cytoplasm spectra, we plotted the 
difference in subtracted spectra between drug treated cells and control cells (Fig. 4c). They 
were similar to the drug solution spectra (Fig. 4d), suggesting that the increases were due to 
drug accumulation in the cytoplasm. Based on the calibration of pure drug solutions, the 
cytosolic concentrations of both drugs were calculated to be around 2–3 mM, about 40–50 
fold increase compared to extracellular concentration (Fig. 4e). The reason of such cytosolic 
enrichment remains unclear and requires further investigation.
Time course of drug uptake into lysosomes
Both the membrane permeation dynamics and thermodynamic equilibrium partition are 
important in determining the lysosomal uptake of drugs. To quantitatively evaluate the 
uptake rate of drugs into the lysosome, we performed hsSRS imaging of drug treated cells at 
different time points and determined the lysosomal concentrations of both imatinib and 
nilotinib. Fig. 5a and 5b show the average SRS spectra of different subcellular components 
in BaF3/BCR-ABL1 cells (n=6) at 1, 2, 4 and 8 hours for imatinib and nilotinib, respectively 
(supplementary Fig. S6 shows representative SRS images at 1305 cm−1). The lysosome SRS 
spectra exhibited large cell-to-cell variations, which could be due to different lysosome pH 
or different cell cycle stages. Fig. 5c and 5d show the calculated apparent concentration of 
lysosomal drugs as a function of incubation time. Compared to the extracellular drug 
concentration of 20 μM, both drugs were enriched over 1000-fold in the lysosome within 
several hours. We note that even at 8 hours, both drug accumulations do not reach steady-
state. Effective accumulated drug concentrations keep increasing. Similar phenomena has 
been observed before for clofazimine, an antibiotic drug that is known to form insoluble 
aggregates in cells13. The non-steady state behavior deviates from that predicted by De 
Duve’s theory. In the case of nilotinib, we believe the deviation is due to slow drug 
precipitation, which increases the size of precipitates and the apparent drug concentration 
over time; in the case of imatinib, the deviation could be due to formation of other 
complexes or drug degradation.
The rate of nilotinib enrichment was much higher than that of imatinib, which is consistent 
with the presumption that only the neutral form of the drug is permeable through the 
lysosome membrane. At cytosolic pH, nilotinib has a much larger fraction of molecules in 
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Accompanying the increase of drug accumulation over time, the number and size of 
lysosomes containing drugs often increased (supplementary Fig. S6). After 8 hours of 
incubation, some cells already showed signs of apoptosis, such as disappearance of nucleus 
structure.
Lysosome-mediated chloroquine-TKI drug interaction
Drug distribution within cells is important for drug efficacy. Although many anticancer drug 
including TKIs are weakly basic and therefore subject to lysosomal trapping, the clinical 
implications of this effect are often overlooked, due to the lack of quantitative 
measurements. Lysosomal trapping of drugs may have two important consequences: first, it 
effectively decreases cytosolic drug concentration; second, it can inhibit autophagy by 
disrupting autophagosome fusion with lysosomes31. The predominant explanation for the 
drug sensitization effect of chloroquine and hydroxychloroquine in TKI treatment of CML 
and several other cancers is that they inhibit autophagy, which plays a key role in the 
survival of cancer cells (including cancer stem cells). Despite the many different studies of 
the autophagy-inducing effect of TKI drugs, the assessment of intracellular interactions of 
drug combinations remains elusive. Here we demonstrate that hsSRS imaging can directly 
image and quantify TKI drug interactions with chloroquine and the dynamics of drug 
enrichment in lysosomes.
We incubated BaF3/BCR-ABL1 cells with both 20 μM imatinib and chloroquine at two 
concentrations of either 20 or 50 μM for 3 hours. hsSRS imaging data show clear contrast 
changes in the lysosomes with increasing chloroquine concentrations (supplementary Movie 
S3, Fig. 6a–c). We further quantified the spectral change (Fig. 6d). The spectral peak at 
1370 cm−1 corresponding to chloroquine increased in amplitude as chloroquine 
concentration increased from 0 to 50 μM. Accompanying this change, the intensity of the 
spectral peak at 1305 cm−1 corresponding to imatinib decreased to almost the same level as 
that of cytoplasm. The lysosomal concentration of imatinib decreased by roughly 5-fold at 
20 μM chloroquine concentration, and by more than 10-fold at 50 μM chloroquine 
concentration (Fig. 6d). This measurement suggests that imatinib is driven out of the 
lysosome due to the accumulation of chloroquine. It can be explained by the two drugs’ 
competition for protons: chloroquine is a stronger base with two protonation sites that have a 
pKa > 8, while imatinib is a weaker base having only one protonation site that has a pKa > 8. 
Chloroquine protonation increases the intra-lysosomal pH and reduces imatinib 
accumulation in lysosomes. If acid-base equilibrium plays the major role here, the intra-
lysosomal pH must have increased by at least one unit upon incubation in 50 μM 
chloroquine solution, which agrees with previous measurement by pH-dependent 
fluorescence32,33. We conclude that lysosome mediated drug interaction of imatinib and 
chloroquine can effectively reduce lysosomal trapping of imatinib and increase its cytosolic 
availability. This offers an alternative explanation of the sensitization effect of chloroquine 
in imatinib based CML chemotherapy4. Cell-based assays confirmed this finding - 
chloroquine not only sensitized BaF3/BCR-ABL1 cells from imatinib (supplementary Table 
S1) but also shifted imatinib’s EC50 in the phospho-Stat5 assay (supplementary Table S2).
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tSurprisingly, when BaF3/BCR-ABL1 cells were treated with 20 μM nilotinib and either 20 
or 50 μM chloroquine simultaneously for 3 hours, we did not observe any significant 
reduction of nilotinib accumulation, even though chloroquine concentration still increases in 
lysosomes (Fig. 6e–h). Considering that chloroquine can increase the pH by about one unit 
to pH = 5–6, the theoretical enrichment of nilotinib would be less than 10-fold based on 
acid-base equilibrium considerations. This small enrichment factor cannot explain the high 
accumulation ratio observed. We suspect that the faster dynamics of nilotinib precipitation 
inside the lysosome is responsible for this phenomenon. Nilotinib diffuses into lysosomes 
faster than chloroquine and forms precipitates before the pH is elevated by chloroquine 
accumulation. This phenomenon would change with lower nilotinib concentration. 
However, directly observing such effects would require at least ten times higher SRS 
detection sensitivity than currently achievable.
CONCLUSIONS
In summary, hsSRS combines the high specificity of Raman spectroscopy with the high 
sensitivity provided by SRS microscopy, which allows for unprecedented capability in label-
free imaging of drug-cell interaction at subcellular resolution. Most TKI drugs have 
lysosomotropic properties, rendering them amenable to lysosomal trapping. At 20 μM 
concentration, both imatinib and nilotinib are enriched by more than 1000-fold in 
lysosomes, which can be explained by De Duve’s theory modified with the addition of 
solubility equilibrium. This large enrichment reduces the availability of cytosolic drug and 
thus decreases drug efficacy. In CML patients treated with these two drugs, mean blood 
plasma trough concentrations of imatinib and nilotinib are 4 μM and 2μM34,35, respectively. 
They are 5–10 times lower than the concentration used in this experiment. Nevertheless, we 
have shown that even at 4 μM drug concentration, we were able to observe drug enrichment 
in lysosome using hsSRS imaging. More importantly, for imatinib, which does not 
precipitate after enrichment, the enrichment factor is independent on drug concentration. 
Thus the lysosomal trapping of imatinib will reduce its efficacy in CML patients. The effect 
would be even more severe for drugs that have large enrichment (high pKa) and low water 
solubility.
We have further shown that hsSRS imaging can directly monitor the interaction of imatinib 
with chloroquine. We determined that 50 μM of chloroquine can increase the pH of 
lysosome by at least one unit, which results in a 10-fold decrease of lysosomal imatinib 
enrichment. We believe this lysosome-mediated drug interaction is at least partly 
responsible for the sensitizing effect of chloroquine for imatinib-treated CML patients. 
Because lysosomotropism is such a universal mechanism based mostly on the acid-base 
equilibrium partition of weakly basic molecules on the two sides of the lysosomal 
membrane, the synergistic effect must also be applicable to other weakly basic drugs and 
cancer cells as well. However, the lysosome-mediated interaction would be strongest for 
drugs that have pKa > 6. For drugs that have lower pKa such as nilotinib, such interaction is 
expected to be weaker. Another caveat is that the dynamics of drug uptake may also play an 
important role. Faster uptake of nilotinib and the precipitation that follows can significantly 
lower the impact of chloroquine accumulation induced lysosomal pH increase.
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quantified at submicron resolution; we also demonstrate the first quantitative measurement 
of drug-drug interaction with label-free imaging. Further improvement in SRS sensitivity 
will enable this technique to be broadly applicable to the study of many different drugs in 
living cells. This could potentially be achieved with higher power lasers in combination with 
longer wavelength to reduce photodamage. We have shown hsSRS imaging in the 
fingerprint region, especially focused on C=C stretching and aromatic ring breathing. It is 
worth noting that it is also possible to design deuterated drugs or alkyne tagged drugs for 
which the physical and chemical properties are largely intact, but their Raman signals are 
shifted into a low background region36, enabling easier and more sensitive SRS detection.
METHODS
Materials
Imatinib and nilotinib were obtained from Novartis. Chloroquine, GNF-2, and GNF-5 were 
purchased from Sigma-Aldrich. 3-Methyladenine was purchased from R&D systems. 
Lysotracker Red was purchased from Lonza. Interleukine-3 was purchased from 
Calbiochem.
Cell culture
The murine bone marrow-derived cell line BaF3 was used to generate the appropriate cell 
line models. BaF3 cells were obtained from the German Collection of Microorganisms and 
Cell Cultures (DSMZ, Braunschweig and DSMZ No. ACC 300). Parental BaF3 cells depend 
on interleukine-3 (IL-3) for growth and survival and were used as the reference cell line that 
does not depend on BCR-ABL1 activity for growth and survival37. These cells are referred 
to as BaF3/wt. To generate BaF3 cells that depend on BCR-ABL1 expression for growth 
and survival, BaF3 cells were engineered to express BCR-ABL1 using retroviral 
transduction with a MSCV based retroviral vector containing a p210 BCR-ABL1 expression 
cassette. When grown in the absence of IL-3, the proliferation of the cells is dependent on 
the expression of BCR-ABL138. These cells are referred to as BaF3/BCR-ABL1. BaF3/
BCR-ABL1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 
1% Pen/Strep. BaF3/wt cells were cultured in RPMI 1640 medium supplemented with 10% 
FBS, 1% Pen/Strep and 5ng/ml mouse IL-3. Both cells were grown in suspension at 37°C 
with 5% CO2 and were passaged every other day with a 1:5 split ratio.
Hyperspectral SRS imaging
The experimental setup we used for fingerprint hsSRS imaging was published previously24 
(supplementary Fig. S1). In brief, two synchronized femtosecond lasers were chirped to 
about 2 ps using SF57 glass rods. One laser was fixed at 1040 nm wavelength and the other 
was tunable from 750 nm to 970 nm. We chose the center wavelength of the tunable laser to 
be at 914 nm and 890 nm for hsSRS imaging in the 1300 cm−1 region and 1600 cm−1 
region, respectively. The wavenumbers were calibrated with oleic acid spectral peaks using 
linear fitting. Spectral resolution is about 20–30 cm−1. The temporal delay between the two 
pulsed lasers was controlled by a motorized stage (Newport MFA-PP). A 60X water 
immersion objective (Olympus UPLSAPO60X, NA = 1.2) was used to focus the lasers onto 
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mW for the Stokes beam. Each SRS image has 512 × 512 pixels and takes 1.65 sec to 
acquire.
hsSRS imaging of drug treated cells
Imatinib, nilotinib, GNF-2 and GNF-5 were dissolved in deuterated DMSO at 10 mM stock 
concentration. For drug treatment studies, different amounts of drug stock solution were 
added to freshly passaged cell suspensions and were grown in the incubator for a few hours. 
Even though some drugs (especially nilotinib) have poor solubility in water, they all have 
excellent solubility in DMSO (> 50 mM). We did not observe any precipitation of the drugs 
in the culture medium at all conditions. Before imaging, 20 μL of cell suspension were 
deposited onto a coverslip with a pipette. A coverslide was immediately applied on top to 
form a single layer of cells, which were then sealed with nail polish. Cells were immediately 
imaged at room temperature within 20 minutes.
To obtain lysosomal drug SRS spectra, ROIs of lysosomes were first selected based on their 
SRS intensity at 1305 cm−1. Typical size of a ROI can range from 0.5μm–3μm. Paired 
background SRS spectra were obtained from cytoplasmic ROI regions that do not contain 
any bright lysosomal drug inclusions. To calculate lysosomal drug concentration, the 
background SRS spectra were subtracted from the lysosomal spectra. The peak intensities of 
the resulting spectra were used to calculate the concentration of drugs by comparing them to 
peak SRS intensities of pure drug solutions at 100 mM.
Two-photon fluorescence imaging of Lysotracker Red
The same lasers used for SRS imaging can excite Lysotracker fluorescence based on two-
photon excitation. We used a bandpass filter (605 nm/55 nm) to select the two-photon 
fluorescence of Lysotracker Red and detected it with a PMT amplifier (Hamamatsu). The 
epi-fluorescence signal from PMT and SRS signal from the photodiode were detected 
simultaneously during the beam scanning.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Structure and spectral properties of five drug molecules imatinib, nilotinib, 
chloroquine, GNF-2, and GNF-5
a, Chemical structures of the drug molecules. b, spontaneous Raman spectra of the drug 
molecules in the fingerprint region from 700 cm−1 to 1700 cm−1. The major peaks used for 
SRS imaging for each drug are marked with shaded vertical lines (~1300 cm−1 for imatinib 
and nilotinib, 1370 cm−1 for chloroquine, and ~1600 cm−1 for GNF2 and GNF5).
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tFigure 2. hsSRS microscopy reveals enrichment of drugs in living cells: the SRS spectra of bright 
spots in drug-treated cells match the SRS spectra of the drug in solution, but differ from that of 
cytosol
a, Representative SRS images at 1305 cm−1 of 20 μM imatinib treated BaF3/BCR-ABL1 
cells for 4 hours. b, Representative SRS images at 1305 cm−1 of 20 μM nilotinib treated 
BaF3/BCR-ABL1 cells for 4 hours. c. Representative SRS images at 1305 cm−1 of control 
cells treated with DMSO. d, SRS spectra of selected ROI (yellow polygon) in a and b. e, 
SRS spectra of 100 mM imatinib and 100 mM nilotinib solutions. f, comparison of average 
SRS spectra of cytosol (excluding brighter regions, n = 6) of imatinib treated, nilotinib 
treated and control BaF3/BCR-ABL1 cells. Scale bar: 5 μm.
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tFigure 3. Accumulations of drugs in lysosomes are confirmed by simultaneous two-photon 
fluorescence imaging of lysotracker and SRS imaging of drug accumulation
a–b, Maximum intensity projection of three-dimensional SRS images at 1305 cm−1 (a) and 
Lysotracker-Red fluorescence images (b) of 20 μM imatinib treated BAF3/BCR-ABL1 cells 
for 4 hours. c, Spatial overlap of the fluorescence image (red) and SRS image (green). d–e, 
Maximum intensity projection of three-dimensional SRS images at 1305 cm−1 (d) and 
Lysotracker-Red fluorescence images (e) of 20 μM nilotinib treated BaF3 cells for 4 hours. 
f, Spatial overlap of the fluorescence image (red) and SRS image (green). g–h, Maximum 
intensity projection of three-dimensional SRS images at 1305 cm−1 (g) and Lysotracker-Red 
fluorescence images (h) of control BaF3 cells. Scale bar: 5μm. j, Modified thermodynamic 
equilibrium model on lysosomotropism which includes solubility equilibrium. Protonated 
drug (DH+) needs to be deprotonated (neutral form D) in order to diffuse through the plasma 
membrane and the lysosomal membrane. Inside the lysosome, the drug exists mainly in 
protonated form due to the low pH and is no longer membrane-permeable. When the 
concentration of the protonated drug goes beyond its solubility, it would precipitate 
(DH+A−) inside the lysosome with counter ion A−.
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tFigure 4. hsSRS imaging of intracellular uptake of GNF-2/GNF-5 drug show that only cytoplasm 
spectra has moderate intensity increases at ~1600 cm−1 due to drug accumulation
a, Representative SRS images at 1600 cm−1 of control BaF3/BCR-ABL1 cells, GNF-2 
treated BaF3/BCR-ABL1 cells, and GNF-5 treated BaF3 cells show that both GNF-2 and 
GNF-5 selectively accumulate in the cytoplasm. b, Average SRS spectra (n =6) of cytosol 
(red), and nucleus (green) for control cells, GNF-2 treated cells, and GNF-5 treated cells. c, 
Subtraction of GNF-2 cytoplasm-nucleus difference spectra with that of control (pink) and 
subtraction of GNF5 cytoplasm-nucleus difference spectra with that of control cell (cyan). d, 
SRS spectra of 100 mM GNF-2 and GNF-5 solutions. Shaded area of the same color 
indicated the standard deviation of SRS spectral measurement on six cells. e, Calculated 
concentrations of GNF2 and GNF5 in the cytoplasm of drug treated BaF3/BCR-ABL1 cells. 
Scale bar: 5 μm.
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tFigure 5. Time course of lysosomal drug uptake monitored by hsSRS imaging reveal that both 
imatinib and nilotinib are enriched over 1000-fold in the lysosome within a few hours, and they 
do not reach steady-state even after 8 hours; the rate of nilotinib enrichment is higher than that 
of imatinib
a, Average SRS spectra of lysosome (blue), cytosol (red) and nucleus (blue) at 1, 2, 4 and 8 
hours for imatinib treated BaF3/BCR-ABL1 cells (n=6). Shaded curves show corresponding 
standard deviation of the spectra of different cells. At 8 hrs, the nuclei of some cells were 
not visible and therefore the nucleus spectra were not plotted for imatinib treated cells. b, 
Average SRS spectra of lysosome (blue), cytosol (red) and nucleus (blue) at 1, 2, 4 and 8 
hours for nilotinib treated BaF3/BCR-ABL1 cells (n=6). c–d, Lysosomal drug concentration 
increases with incubation time as calculated from SRS spectra in a and b, respectively. The 
error bars are standard deviations of calculated drug concentrations of the six cell samples at 
each time point.
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tFigure 6. Intracellular interaction of TKI drugs with chloroquine measured by hsSRS imaging 
show that the increase of chloroquine accumulation (SRS peak at 1370 cm−1) in the lysosome 
significantly reduce imatinib but not nilotinib enrichment in the lysosome (both have SRS peak 
at 1305 cm−1)
a–c, e–g, SRS spectra of lysosomes, cytosol and nucleus for BaF3/BCR-ABL1 cells treated 
with different combinations of drugs for 3 hours: 20 μM imatinib (a), 20 μM imatinib + 20 
μM chloroquine (b), 20 μM imatinib + 50 μM chloroquine (c), 20 μM nilotinib (e), 20 μM 
nilotinib + 20 μM chloroquine (f), and 20 μM nilotinib + 50 μM chloroquine (g). d, h, To 
visualize the drug accumulation induced spectra change, the difference spectra of lysosome 
and cytosol are plotted: difference spectra of imatinib treated cells at increasing chloroquine 
concentrations corresponding to a (red), b (green) and c (blue), respectively (d) and 
difference spectra of nilotinib treated cells at different chloroquine concentrations 
corresponding to e (red), f (green) and g (blue), respectively (h). Shaded curves show 
corresponding standard deviation of measurement on six different cells.
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